DS
ZNTL icon

David Shaw’s Zentalis Pharmaceuticals ZNTL Stock Holding History

David Shaw’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.65M Sell
546,566
-937,532
-63% -$3.74M ﹤0.01% 2958
2026
Q1 		$3.47M Sell
1,484,098
-176,280
-11% -$455K ﹤0.01% 2461
2025
Q4 		$2.24M Buy
1,660,378
+251,575
+18% +$366K ﹤0.01% 2962
2025
Q3 		$2.13M Buy
1,408,803
+211,179
+18% +$317K ﹤0.01% 2931
2025
Q2 		$1.39M Buy
1,197,624
+79,847
+7% +$105K ﹤0.01% 3006
2025
Q1 		$1.78M Sell
1,117,777
-121,682
-10% -$262K ﹤0.01% 2694
2024
Q4 		$3.76M Buy
1,239,459
+110,882
+10% +$363K ﹤0.01% 2216
2024
Q3 		$4.15M Buy
1,128,577
+888,236
+370% +$3.23M ﹤0.01% 2096
2024
Q2 		$983K Buy
240,341
+226,050
+1,582% +$2.52M ﹤0.01% 3221
2024
Q1 		$225K Buy
+14,291
New +$197K ﹤0.01% 3878
2023
Q4 		– Sell
-37,439
Closed -$751K – 4671
2023
Q3 		$751K Buy
+37,439
New +$950K ﹤0.01% 3238
2022
Q4 		– Sell
-29,112
Closed -$631K – 5174
2022
Q3 		$631K Sell
29,112
-25,633
-47% -$701K ﹤0.01% 3893
2022
Q2 		$1.54M Buy
54,745
+33,786
+161% +$895K ﹤0.01% 3298
2022
Q1 		$967K Buy
20,959
+2,867
+16% +$155K ﹤0.01% 3945
2021
Q4 		$1.52M Sell
18,092
-36,346
-67% -$2.81M ﹤0.01% 3598
2021
Q3 		$3.63M Sell
54,438
-2,016
-4% -$116K ﹤0.01% 2433
2021
Q2 		$3M Buy
56,454
+34,283
+155% +$1.84M ﹤0.01% 2529
2021
Q1 		$962K Sell
22,171
-23,116
-51% -$995K ﹤0.01% 3145
2020
Q4 		$2.35M Buy
45,287
+37,294
+467% +$1.68M ﹤0.01% 2452
2020
Q3 		$261K Sell
7,993
-16,942
-68% -$593K ﹤0.01% 3505
2020
Q2 		$1.2M Buy
+24,935
New +$956K ﹤0.01% 2797

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

David Shaw's ZNTL Position: Q2 2026 in Review

David Shaw reduced its Zentalis Pharmaceuticals (ZNTL) stake by 63% in Q2 2026, selling an estimated $3.74M and leaving 546,566 shares worth $2.65M. The position accounts for ﹤0.01% of the portfolio, ranked #2958.

David Shaw first reported a position in ZNTL in Q2 2020 and has held it in 21 quarters since. The position peaked at $4.15M in Q3 2024. 113 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • David Shaw held 546,566 shares of Zentalis Pharmaceuticals worth $2.65M as of Q2 2026.
  • David Shaw sold 937,532 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $3.74M.
  • Zentalis Pharmaceuticals made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2958 holding.
  • David Shaw first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 21 quarters since.
  • David Shaw's Zentalis Pharmaceuticals position peaked at $4.15M in Q3 2024.
  • 113 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.